Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats
Rationale and objectives
Simultaneous alcohol and nicotine consumption occurs in the majority of individuals with alcohol use disorder (AUD) and nicotine dependence. Varenicline (Var) is used to assist in the cessation of nicotine use, while naltrexone (Nal) is the standard treatment for AUD. Despite evidence that ethanol (EtOH) and nicotine (NIC) co-use produces unique neuroadaptations, preclinical research has focused on the effects of pharmacotherapeutics on a single reinforcer. The current experiments examined the effects of Var and Nal on EtOH, NIC, or EtOH+NIC intake.
Animals were randomly assigned to one of four drinking conditions of 24-h access to a three-bottle choice paradigm, one of which always contained water. Drinking conditions were water only, 0.07 and 0.14 mg/mL NIC (NIC only), 15% and 30% EtOH (EtOH only), or 15% and 30% EtOH with 0.14 mg/mL NIC (EtOH+NIC). The effects of Var (0, 1, or 2 mg/kg) or Nal (0, 1, or 10 mg/kg) injections on maintenance and relapse consumption were determined during four consecutive days.
Var reduced maintenance and relapse NIC intake but had no effect on EtOH or EtOH+NIC drinking. Conversely, Nal reduced EtOH maintenance and relapse drinking, but had no effect on NIC or EtOH+NIC drinking.
The results indicate the standard pharmacological treatments for nicotine dependence and AUD were effective at reducing consumption of the targeted reinforcer but neither reduced EtOH+NIC co-use/abuse. These findings suggest that co-abuse may promote unique neuroadaptations that require models of polysubstance abuse to develop pharmacotherapeutics to treat AUD and nicotine dependence.
KeywordsAlcohol-preferring (P) rats Alcohol Ethanol Nicotine Co-abuse Varenicline Naltrexone Maintenance Relapse Addiction
This study was supported by NIAAA grants AA07611, AA07462, AA10721, AA20908, and AA019366.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, Fiore MC (2016) Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial. JAMA 315(4):371–379Google Scholar
- Deehan GJ, Hauser SR, Waeiss RA, Knight CP, Toalston JE, Truitt WA, McBride WJ, Rodd ZA (2015) Co-administration of ethanol and nicotine: the enduring alterations in the rewarding properties of nicotine and glutamate activity within the mesocorticolimbic system of female alcohol-preferring (P) rats. Psychopharmacology 232(23):4293–4302PubMedPubMedCentralCrossRefGoogle Scholar
- Delnevo CD, Wackowski OA, Giovenco DP, Manderski MT, Hrywna M, Ling PM (2012) Examining market trends in the United States smokeless tobacco use: 2005–2011. Tob ControlGoogle Scholar
- Exley R, Maubourguet N, David V, Eddine R, Evrard A, Pons S, Marti F, Threlfell S, Cazala P, McIntosh JM, Changeux JP, Maskos U, Cragg SJ, Faure P (2011) Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine. Proc Natl Acad Sci U S A 108(18):7577–7582PubMedPubMedCentralCrossRefGoogle Scholar
- Froehlich JC, Fischer SM, Dilley JE, Nicholson ER, Smith TN, Filosa NJ, Rademacher LC (2016) Combining varenicline (Chantix) with naltrexone decreases alcohol drinking more effectively than does either drug alone in a rodent model of alcoholism. Alcohol Clin Exp Res 40(9):1961–1970PubMedPubMedCentralCrossRefGoogle Scholar
- Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 296(1):47–55Google Scholar
- Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, McKinney S, Whiteaker P, Bencherif M, Lester HA, Marks MJ (2010) Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*-, α6β2*-, α3β4*- and α7-nicotinic acetylcholine receptors. Neuropharmacology 58(7):1054–1066PubMedPubMedCentralCrossRefGoogle Scholar
- Gurley DA, Lanthorn TH (1998) Nicotinic agonists competitively antagonize serotonin at mouse 5-HT3 receptors expressed in Xenopus oocytes. Neurosci Lett 247(2–3):107–110Google Scholar
- John U, Rumpf H, Hanke M, Gerke P, Hapke U (2003b) Estimation of tobacco- or alcohol-attributable disease rates in national hospital care: an approach based on routine in-patient disease register data and systematic diagnosis of alcohol use disorders. Alcohol Alcohol 38(4):339–346PubMedCrossRefGoogle Scholar
- Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296(1):56–63PubMedCrossRefGoogle Scholar
- Maggio SE, Saunders MA, Baxter TA, Nixon K, Prendergast MA, Zheng G, Crooks P, Dwoskin LP, Slack RD, Newman AH, Bell RL, Bardo MT (2018a) Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. Psychopharmacology 235(5):1439–1453PubMedCrossRefPubMedCentralGoogle Scholar
- Maggio SE, Saunders MA, Nixon K, Prendergast MA, Zheng G, Crooks P, Dwoskin LP, Bell RL, Bardo MT (2018b) An improved model of ethanol and nicotine co-use in female P rats: effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI. Drug Alcohol Depend 193:154–161PubMedCrossRefPubMedCentralGoogle Scholar
- Martell N (2014) Tobacco returns to the bar, this time inside cocktails. National Public Radio. Retrieved from https://www.npr.org/
- Motschman CA, Gass JC, Wray JM, Germeroth LJ, Schlienz NJ, Munoz DA, Moore FE, Rhodes JD, Hawk LW, Tiffany ST (2016) Selection criteria limit generalizability of smoking pharmacotherapy studies differentially across clinical trials and laboratory studies: a systematic review on varenicline. Drug Alcohol Depend 169:180–189PubMedCrossRefPubMedCentralGoogle Scholar
- National Research Council (2011) Guide for the care and use of laboratory animals, 8th edn. The National Academies Press, Washington, DCGoogle Scholar
- New York Times Magazine (Marshall Selladec) (2003) The 3rd Annual Year in Ideas; Nicotini, The. Published Dec 14, 2003Google Scholar
- O’Connor EC, Parker D, Rollema H, Mead AN (2010) The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology 208(3):365–376PubMedCrossRefPubMedCentralGoogle Scholar
- O’Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P (2006) A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 166(6):667–674PubMedCrossRefPubMedCentralGoogle Scholar
- Rodd ZA, Bell RL, McQueen VK, Davids MR, Hsu CC, Murphy JM, Li TK, Lumeng L, McBride WJ (2005) Prolonged increase in the sensitivity of the posterior ventral tegmental area to the reinforcing effects of ethanol following repeated exposure to cycles of ethanol access and deprivation. J Pharmacol Exp Ther 315(2):648–657PubMedPubMedCentralCrossRefGoogle Scholar
- Rodd-Henricks ZA, Bell RL, Kuc KA, Murphy JM, McBride WJ, Lumeng L, Li TK (2002a) Effects of ethanol exposure on subsequent acquisition and extinction of ethanol self-administration and expression of alcohol-seeking behavior in adult alcohol-preferring (P) rats: I. Periadolescent exposure. Alcohol Clin Exp Res 26:1632–1641PubMedCrossRefGoogle Scholar
- Rodd-Henricks ZA, Bell RL, Kuc KA, Murphy JM, McBride WJ, Lumeng L, Li TK (2002b) Effects of ethanol exposure on subsequent acquisition and extinction of ethanol self-administration and expression of alcohol-seeking behavior in adult alcohol-preferring (P) rats: II. Adult exposure. Alcohol Clin Exp Res 26:1642–1652PubMedCrossRefGoogle Scholar
- Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FI, Williams KE (2007) Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52(3):985–994PubMedCrossRefGoogle Scholar
- Thompson A, Ashcroft DM, Owens L, van Staa TP, Pirmohamed M (2017) Drug therapy for alcohol dependence in primary care in the UK: a Clinical Practice Research Datalink study. PLoS One 12(3):1–14Google Scholar
- Toalston JE, Oster SM, Kuc KA, Pommer TJ, Murphy JM, Lumeng L, Bell RL, McBride WJ, Rodd ZA (2008) Effects of alcohol and saccharin deprivations on concurrent ethanol and saccharin operant self-administration by alcohol-preferring (P) rats. Alcohol 42:277–284PubMedPubMedCentralCrossRefGoogle Scholar
- Truitt WA, Hauser SR, Deehan GJ, Toalston JE, Wilden JA, Bell RL, McBride WJ, Rodd ZA (2015) Ethanol and nicotine interaction within the posterior ventral tegmental area in male and female alcohol-preferring rats: evidence of synergy and differential gene activation in the nucleus accumbens shell. Psychopharmacology 232(3):639–649PubMedCrossRefPubMedCentralGoogle Scholar